Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2- Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA-2 Trial.

导出 OA

翻译打印收藏纠错

作者： Véronique,Diéras ^[1] ; Nadia,Harbeck ^[2] ; Anil Abraham,Joy ^[3] ; Karen,Gelmon ^[4] ; Johannes,Ettl ^[5] ; Sunil,Verma ^[6] ; Dongrui R,Lu ^[7] ; Eric,Gauthier ^[8] ; Patrick,Schnell ^[9] ; Ave,Mori ^[10] ; Hope S,Rugo ^[11] ; Richard S,Finn ^[12]

作者单位： Department of Medical Oncology, Centre Eugène Marquis, Rennes, France v.dieras@rennes.unicancer.fr. ^[1] Brustzentrum der Universität München, Munich, Germany. ^[2] Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada. ^[3] British Columbia Cancer Agency, Vancouver, British Columbia, Canada. ^[4] Frauenklinik und Poliklinik Klinikum rechts der Isar, Technische Universität, München, Munich, Germany. ^[5] University of Calgary, Calgary, Alberta, Canada. ^[6] Pfizer Inc., La Jolla, California, USA. ^[7] Pfizer Inc., San Francisco, California, USA. ^[8] Pfizer Inc., New York New York, USA. ^[9] Pfizer s.r.l., Milan, Italy. ^[10] University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California, USA. ^[11] David Geffen School of Medicine at UCLA, Santa Monica, California, USA. ^[12]

关键词 Breast cancer Hematologic Neutropenia Palbociclib Safety

主题词抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);乳腺肿瘤(Breast Neoplasms);女(雌)性(Female);人类(Humans);哌嗪类(Piperazines);绝经后期(Postmenopause);吡啶类(Pyridines)

DOI 10.1634/theoncologist.2019-0019

PMID 31217344

发布时间 2020-09-01

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交